In our study, we revealed the potential values of mucosal HA content or HAS2/MMP3 expression in predicting the therapeutic outcomes related to use of IgG1 mAbs before treatment, suggesting that patients with IBD with high HA or HAS2/MMP3 expression might be less likely to benefit from treatment. The gene discussed is HAS2; the disease is inflammatory bowel disease.